Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21
<p><strong>Introduction: </strong>The high proportion of SARS-CoV-2 infections that have remained undetected presents a challenge to tracking the progress of the pandemic and estimating the extent of population immunity.</p> <p><strong>Methods: &...
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
Public Library of Science
2022
|
| _version_ | 1826310437909561344 |
|---|---|
| author | Lucinde, RK Mugo, D Bottomley, C Karani, A Gardiner, E Aziza, R Gitonga, JN Karanja, H Nyagwange, J Tuju, J Wanjiku, P Nzomo, E Kamuri, E Thuranira, K Agunda, S Nyutu, G Etyang, AO Adetifa, IMO Kagucia, E Uyoga, S Otiende, M Otieno, E Ndwiga, L Agoti, CN Aman, RA Mwangangi, M Amoth, P Kasera, K Nyaguara, A Ng'ang'a, W Ochola, LB Namdala, E Gaunya, O Okuku, R Barasa, E Bejon, P Tsofa, B Ochola-Oyier, LI Warimwe, GM Agweyu, A Scott, JAG Gallagher, KE |
| author_facet | Lucinde, RK Mugo, D Bottomley, C Karani, A Gardiner, E Aziza, R Gitonga, JN Karanja, H Nyagwange, J Tuju, J Wanjiku, P Nzomo, E Kamuri, E Thuranira, K Agunda, S Nyutu, G Etyang, AO Adetifa, IMO Kagucia, E Uyoga, S Otiende, M Otieno, E Ndwiga, L Agoti, CN Aman, RA Mwangangi, M Amoth, P Kasera, K Nyaguara, A Ng'ang'a, W Ochola, LB Namdala, E Gaunya, O Okuku, R Barasa, E Bejon, P Tsofa, B Ochola-Oyier, LI Warimwe, GM Agweyu, A Scott, JAG Gallagher, KE |
| author_sort | Lucinde, RK |
| collection | OXFORD |
| description | <p><strong>Introduction: </strong>The high proportion of SARS-CoV-2 infections that have remained undetected presents a challenge to tracking the progress of the pandemic and estimating the extent of population immunity.</p>
<p><strong>Methods: </strong>We used residual blood samples from women attending antenatal care services at three hospitals in Kenya between August 2020 and October 2021and a validated IgG ELISA for SARS-Cov-2 spike protein and adjusted the results for assay sensitivity and specificity. We fitted a two-component mixture model as an alternative to the threshold analysis to estimate of the proportion of individuals with past SARS-CoV-2 infection.</p>
<p><strong>Results: </strong>We estimated seroprevalence in 2,981 women; 706 in Nairobi, 567 in Busia and 1,708 in Kilifi. By October 2021, 13% of participants were vaccinated (at least one dose) in Nairobi, 2% in Busia. Adjusted seroprevalence rose in all sites; from 50% (95%CI 42–58) in August 2020, to 85% (95%CI 78–92) in October 2021 in Nairobi; from 31% (95%CI 25–37) in May 2021 to 71% (95%CI 64–77) in October 2021 in Busia; and from 1% (95% CI 0–3) in September 2020 to 63% (95% CI 56–69) in October 2021 in Kilifi. Mixture modelling, suggests adjusted cross-sectional prevalence estimates are underestimates; seroprevalence in October 2021 could be 74% in Busia and 72% in Kilifi.</p>
<p><strong>Conclusions: </strong>There has been substantial, unobserved transmission of SARS-CoV-2 in Nairobi, Busia and Kilifi Counties. Due to the length of time since the beginning of the pandemic, repeated cross-sectional surveys are now difficult to interpret without the use of models to account for antibody waning.</p> |
| first_indexed | 2024-03-07T07:51:18Z |
| format | Journal article |
| id | oxford-uuid:bdd4d950-b9e7-4edb-a5b2-cdb066fd9bd2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:51:18Z |
| publishDate | 2022 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:bdd4d950-b9e7-4edb-a5b2-cdb066fd9bd22023-07-17T06:48:11ZSero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bdd4d950-b9e7-4edb-a5b2-cdb066fd9bd2EnglishSymplectic ElementsPublic Library of Science2022Lucinde, RKMugo, DBottomley, CKarani, AGardiner, EAziza, RGitonga, JNKaranja, HNyagwange, JTuju, JWanjiku, PNzomo, EKamuri, EThuranira, KAgunda, SNyutu, GEtyang, AOAdetifa, IMOKagucia, EUyoga, SOtiende, MOtieno, ENdwiga, LAgoti, CNAman, RAMwangangi, MAmoth, PKasera, KNyaguara, ANg'ang'a, WOchola, LBNamdala, EGaunya, OOkuku, RBarasa, EBejon, PTsofa, BOchola-Oyier, LIWarimwe, GMAgweyu, AScott, JAGGallagher, KE<p><strong>Introduction: </strong>The high proportion of SARS-CoV-2 infections that have remained undetected presents a challenge to tracking the progress of the pandemic and estimating the extent of population immunity.</p> <p><strong>Methods: </strong>We used residual blood samples from women attending antenatal care services at three hospitals in Kenya between August 2020 and October 2021and a validated IgG ELISA for SARS-Cov-2 spike protein and adjusted the results for assay sensitivity and specificity. We fitted a two-component mixture model as an alternative to the threshold analysis to estimate of the proportion of individuals with past SARS-CoV-2 infection.</p> <p><strong>Results: </strong>We estimated seroprevalence in 2,981 women; 706 in Nairobi, 567 in Busia and 1,708 in Kilifi. By October 2021, 13% of participants were vaccinated (at least one dose) in Nairobi, 2% in Busia. Adjusted seroprevalence rose in all sites; from 50% (95%CI 42–58) in August 2020, to 85% (95%CI 78–92) in October 2021 in Nairobi; from 31% (95%CI 25–37) in May 2021 to 71% (95%CI 64–77) in October 2021 in Busia; and from 1% (95% CI 0–3) in September 2020 to 63% (95% CI 56–69) in October 2021 in Kilifi. Mixture modelling, suggests adjusted cross-sectional prevalence estimates are underestimates; seroprevalence in October 2021 could be 74% in Busia and 72% in Kilifi.</p> <p><strong>Conclusions: </strong>There has been substantial, unobserved transmission of SARS-CoV-2 in Nairobi, Busia and Kilifi Counties. Due to the length of time since the beginning of the pandemic, repeated cross-sectional surveys are now difficult to interpret without the use of models to account for antibody waning.</p> |
| spellingShingle | Lucinde, RK Mugo, D Bottomley, C Karani, A Gardiner, E Aziza, R Gitonga, JN Karanja, H Nyagwange, J Tuju, J Wanjiku, P Nzomo, E Kamuri, E Thuranira, K Agunda, S Nyutu, G Etyang, AO Adetifa, IMO Kagucia, E Uyoga, S Otiende, M Otieno, E Ndwiga, L Agoti, CN Aman, RA Mwangangi, M Amoth, P Kasera, K Nyaguara, A Ng'ang'a, W Ochola, LB Namdala, E Gaunya, O Okuku, R Barasa, E Bejon, P Tsofa, B Ochola-Oyier, LI Warimwe, GM Agweyu, A Scott, JAG Gallagher, KE Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21 |
| title | Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21 |
| title_full | Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21 |
| title_fullStr | Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21 |
| title_full_unstemmed | Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21 |
| title_short | Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21 |
| title_sort | sero surveillance for igg to sars cov 2 at antenatal care clinics in three kenyan referral hospitals repeated cross sectional surveys 2020 21 |
| work_keys_str_mv | AT lucinderk serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT mugod serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT bottomleyc serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT karania serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT gardinere serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT azizar serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT gitongajn serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT karanjah serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT nyagwangej serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT tujuj serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT wanjikup serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT nzomoe serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT kamurie serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT thuranirak serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT agundas serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT nyutug serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT etyangao serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT adetifaimo serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT kaguciae serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT uyogas serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT otiendem serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT otienoe serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT ndwigal serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT agoticn serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT amanra serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT mwangangim serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT amothp serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT kaserak serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT nyaguaraa serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT ngangaw serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT ocholalb serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT namdalae serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT gaunyao serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT okukur serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT barasae serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT bejonp serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT tsofab serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT ocholaoyierli serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT warimwegm serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT agweyua serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT scottjag serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 AT gallagherke serosurveillanceforiggtosarscov2atantenatalcareclinicsinthreekenyanreferralhospitalsrepeatedcrosssectionalsurveys202021 |